Skip to main content

 Scientific publications

Prognostic value of adipose tissue and muscle mass in advanced colorectal cancer: a post hoc analysis of two non-randomized phase II trials.

Authors : Charette N, Vandeputte C, Ameye L, Bogaert CV, Krygier J, Guiot T, Deleporte A, Delaunoit T, Geboes K, Van Laethem JL, Peeters M, Demolin G, Holbrechts S, Flamen P, Paesmans M, Hendlisz A
Year : 2019
Journal : BMC Cancer
Volume : 19
Pages : 134

PD-1 and PD-L1 inhibitors in oesophago-gastric cancers.

Authors : Akin Telli T, Bregni G, Camera S, Deleporte A, Hendlisz A, Sclafani F
Year : 2019
Journal : Cancer Lett

Circulating tumor DNA in early response assessment and monitoring of advanced colorectal cancer treated with a multi-kinase inhibitor.

Authors : Vandeputte C, Kehagias P, El Housni H, Ameye L, Laes JF, Desmedt C, Sotiriou C, Deleporte A, Puleo F, Geboes K, Delaunoit T, Demolin G, Peeters M, DHondt L, Janssens J, Carrasco J, Marechal R, Gomez Galdon M, Heimann P, Paesmans M, Flamen P, Hendlisz A
Year : 2018
Journal : Oncotarget
Volume : 9
Pages : 17756-17769

Selective internal radiation therapy (SIRT) before partial hepatectomy or radiofrequency destruction for treatment of hepatocellular carcinoma in cirrhotic patients: a feasibility and safety pilot study.

Authors : Lemaire M, Lucidi V, Bouazza F, Katsanos G, Vanderlinden B, Levillain H, Delatte P, Garcia CA, Vouche M, Gomez Galdon M, Demetter P, Deleporte A, Hendlisz A, Flamen P, Donckier V
Year : 2018
Journal : HPB (Oxford)
Volume : 20(7)
Pages : 641-648

Accuracy of FDG-PET/CT in Colorectal Peritoneal Carcinomatosis: Potential Tool for Evaluation of Chemotherapeutic Response.

Authors : Liberale G, Lecocq C, Garcia C, Muylle K, Covas A, Deleporte A, Hendlisz A, Bouazza F, El Nakadi I, Flamen P
Year : 2017
Journal : Anticancer Res
Volume : 37
Pages : 929-934

Monitoring metabolic response using FDG PET-CT during targeted therapy for metastatic colorectal cancer.

Authors : Woff E, Hendlisz A, Garcia C, Deleporte A, Delaunoit T, Maréchal R, Holbrechts S, Van den Eynde M, Demolin G, Vierasu I, Lhommel R, Gauthier N, Guiot T, Ameye L, Flamen P
Year : 2016
Journal : Eur J Nucl Med Mol Imaging
Volume : 43(10)
Pages : 1792-801

A phase I study of two dosing schedules of oral BI 847325 in patients with advanced solid tumors.

Authors : Schöffski P, Aftimos P, Dumez H, Deleporte A, De Block K, Costermans J, Billiet M, Meeus MA, Lee C, Schnell D, Goeldner RG, Awada A
Year : 2016
Journal : Cancer Chemother Pharmacol
Volume : 77(1)
Pages : 99-108

The Prognostic Significance of Metabolic Response Heterogeneity in Metastatic Colorectal Cancer.

Authors : Hendlisz A, Deleporte A, Delaunoit T, Maréchal R, Peeters M, Holbrechts S, Van den Eynde M, Houbiers G, Filleul B, Van Laethem JL, Ceyssens S, Barbuto AM, Lhommel R, Demolin G, Garcia C, El Mansy H, Ameye L, Moreau M, Guiot T, Paesmans M, Piccart-Gebhart M, Flamen P
Year : 2015
Journal : PLoS ONE
Volume : 10
Pages : e0138341

Radioembolisation and portal vein embolization before resection of large hepatocellular carcinoma.

Authors : Bouazza F, Poncelet A, Garcia CA, Delatte P, Engelholm JL, Gomez Galdon M, Deleporte A, Hendlisz A, Vanderlinden B, Flamen P, Donckier V
Year : 2015
Journal : World J Gastroenterol
Volume : 21
Pages : 9666-70

Regorafenib assessment in refractory advanced colorectal cancer: RegARd-C study protocol.

Authors : Hendlisz A, Deleporte A, Vandeputte C, Charette N, Paesmans M, Guiot T, Garcia C, Flamen P
Year : 2015
Journal : BMJ Open
Volume : 5(3)
Pages : e007189

Erratum: Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): Protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study.

Authors : Hendlisz A, Golfinopoulos V, Deleporte A, Paesmans M, El Mansy H, Garcia C, Peeters M, Annemans L, Vandeputte C, Maetens M, Van den Eynde M, Maréchal R, Borbath I, Dresse D, Houbiers G, Fried M, Awada A, Piccart-Gebhart M, Van Laethem JL, Flamen P
Year : 2015
Journal : BMC Cancer
Volume : 15
Pages : 173

Correlating tumor metabolic progression index measured by serial FDG PET-CT, apparent diffusion coefficient measured by magnetic resonance imaging (MRI) and blood genomics to patient's outcome in advanced colorectal cancer: the CORIOLAN study.

Authors : Deleporte A, Paesmans M, Garcia C, Vandeputte C, Lemort M, Engelholm JL, Hoerner F, Aftimos P, Awada A, Charette N, Machiels G, Piccart-Gebhart M, Flamen P, Hendlisz A
Year : 2014
Journal : BMC Cancer
Volume : 14(1)
Pages : 385

In times of crisis, go liquid!

Authors : Hendlisz A, Deleporte A, Vandeputte C
Year : 2014
Journal : Curr Opin Oncol
Volume : 26(4)
Pages : 440

The Role of Age on Dose Limiting Toxicities (DLTs) in Phase I Dose-escalation Trials.

Authors : Schwandt A, Harris PJ, Hunsberger S, Deleporte A, Smith GL, Vulih D, Anderson BD, Ivy SP
Year : 2014
Journal : Clin Cancer Res
Volume : 20(18)
Pages : 4768-75

Selective Internal Radiation Therapy (SIRT) with yttrium-90 resin microspheres plus standard systemic chemotherapy regimen of FOLFOX versus FOLFOX alone as first-line treatment of non-resectable liver metastases from colorectal cancer: the SIRFLOX st

Authors : Gibbs P, Gebski V, Van Buskirk M, Thurston K, Cade DN, Van Hazel GA, + collaborators (among others :, Deleporte A
Year : 2014
Journal : BMC Cancer
Volume : 14
Pages : 897

Academic versus industry-driven research in upper gastrointestinal cancer: sinners and saints.

Authors : Hendlisz A, Charette N, Awada A, Deleporte A
Year : 2013
Journal : Curr Opin Oncol
Volume : 25(4)
Pages : 407-8

Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): Protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study.

Authors : Hendlisz A, Golfinopoulos V, Deleporte A, Paesmans M, Mansy H, Garcia C, Peeters M, Annemans L, Vandeputte C, Maetens M, Borbath I, Dresse D, Houbier G, Fried M, Awada A, Piccart-Gebhart M, Laethem JL, Flamen P
Year : 2013
Journal : BMC Cancer
Volume : 13(1)
Pages : 190

Combination of gemcitabine and cetuximab in patients with advanced cholangiocarcinoma: a phase II study of the Belgian Group of Digestive Oncology.

Authors : Borbath I, Ceratti A, Verslype C, Demols A, Delaunoit T, Laurent S, Deleporte A, Vergauwe P, Van Maanen A, Sempoux C, van Cutsem E, Van Laethem JL
Year : 2013
Journal : Ann Oncol
Volume : 24(11)
Pages : 2824-9

Serial FDG-PET/CT for early outcome prediction in patients with metastatic colorectal cancer undergoing chemotherapy.

Authors : Hendlisz A, Golfinopoulos V, Garcia C, Covas A, Emonts P, Ameye L, Paesmans M, Deleporte A, Machiels G, Toussaint E, Vanderlinden B, Awada A, Piccart-Gebhart M, Flamen P
Year : 2012
Journal : Ann Oncol
Volume : 23(7)
Pages : 1687-93

The confusion around neuroendocrine tumors.

Authors : Hendlisz A, Deleporte A
Year : 2012
Journal : Curr Opin Oncol
Volume : 24(4)
Pages : 431-2